Risk of malignancy in cytologically indeterminate thyroid nodules harboring thyroid stimulating hormone receptor mutations
ObjectivesTo evaluate the frequency and risk of malignancy of TSHRpI568T mutations discovered in indeterminate thyroid nodules (ITN) within the Veracyte CLIA laboratory undergoing Afirma® Genomic Sequencing Classifier (GSC) testing, and to evaluate a broader cohort of TSHR variants and their categor...
Main Authors: | Dorota Whitmer, John E. Phay, Shelby Holt, Benjamin O’Donnell, Jay Nguyen, Dennis Joseph, Anthony Chi, Shuyang Wu, Yangyang Hao, Jing Huang, Joshua P. Klopper, Richard T. Kloos, Giulia C. Kennedy, Joyce Shin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.1073592/full |
Similar Items
-
Cost-effectiveness analysis of molecular testing for cytologically indeterminate thyroid nodules
by: Navjit Dharampal, et al.
Published: (2022-12-01) -
Molecular Tests for Risk-Stratifying Cytologically Indeterminate Thyroid Nodules: An Overview of Commercially Available Testing Platforms in the United States
by: Michiya Nishino, et al.
Published: (2021-05-01) -
Diagnostic Performance of Afirma and Interpace Diagnostics Genetic Testing in Indeterminate Thyroid Nodules: A Single Center Study
by: Emad Kandil, et al.
Published: (2023-03-01) -
Correlation of ultrasound features in the TIRADS scoring system with cytological findings in the FNAC of thyroid nodules and their association with the metabolic status
by: Maha Assem Hussein, et al.
Published: (2024-03-01) -
Molecular Testing for Thyroid Nodules: The Experience at McGill University Teaching Hospitals in Canada
by: Mohannad Rajab, et al.
Published: (2022-08-01)